Journal
STROKE AND VASCULAR NEUROLOGY
Volume 1, Issue 3, Pages 101-107Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/svn-2016-000031
Keywords
SUMO; brain ischemia; neuroprotection; drug discovery; SENP inhibitors
Categories
Funding
- American Heart Association [12SDG11950003]
- National Institutes of Health (NIH) [NS081299]
Ask authors/readers for more resources
Small ubiquitin-like modifier (SUMO) conjugation (SUMOylation) is a post-translational protein modification that modulates almost all major cellular processes, and has been implicated in many human diseases. A growing body of evidence from in vitro and in vivo studies demonstrates that increasing global levels of SUMO conjugated proteins (global SUMOylation) protects cells against ischaemia-induced damage, while suppressing global SUMOylation promotes cell injury after ischaemia. Indeed, SUMOylation has emerged as a potential therapeutic target for neuroprotection in brain ischaemia, including global brain ischaemia and focal brain ischaemia (ischaemic stroke). Here, we summarise findings on the role of SUMOylation in human diseases, brain ischaemia in particular, and review recent developments in drug discovery targeting SUMOylation with a major focus on its neuroprotective applications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available